Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Evercore ISI Group analyst Cory Kasimov initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperform rating and an...
This capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it...
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional impr...
JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $3...
Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price targ...
Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price targ...
The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expect...
Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $60 to $53.
